Date | Time | Source | Announcement |
---|---|---|---|
06 Dec 2007 | 07:01 AM | Initiation of Phase IIb trial | |
16 Nov 2007 | 12:28 PM | Appointment of Nomad | |
28 Sep 2007 | 07:02 AM | Interim Results | |
22 Aug 2007 | 07:00 AM | Compound Discovery | |
20 Aug 2007 | 10:17 AM | AIM Rule 26 | |
13 Aug 2007 | 04:17 PM | Directors' Dealing | |
06 Aug 2007 | 02:40 PM | Grant of Options | |
10 Jul 2007 | 07:01 AM | Pivotal phase II/III trial | |
13 Jun 2007 | 02:00 PM | AGM and Board Update | |
01 May 2007 | 07:01 AM | Preliminary Results | |
27 Apr 2007 | 03:57 PM | Board Appointment | |
15 Feb 2007 | 07:00 AM | Appointment of adviser | |
07 Feb 2007 | 07:00 AM | Board Changes | |
19 Jan 2007 | 08:57 AM | Total Voting Rights | |
05 Jan 2007 | 02:27 PM | Issue of Equity | |
27 Dec 2006 | 02:53 PM | Total Voting Rights | |
21 Dec 2006 | 07:00 AM | Issue of Equity | |
30 Oct 2006 | 07:00 AM | Further Phase II Data | |
17 Oct 2006 | 07:00 AM | Phase II Data | |
02 Oct 2006 | 07:00 AM | FDA Meeting on Lupus | |
26 Sep 2006 | 07:00 AM | Interim Results | |
01 Aug 2006 | 07:00 AM | Preliminary Results | |
05 Jul 2006 | 07:00 AM | Start of phase II trial | |
12 Jun 2006 | 05:04 PM | Accounting reference dates | |
10 May 2006 | 07:00 AM | Phase 1 Lupus results | |
11 Apr 2006 | 07:00 AM | Research Grants | |
07 Oct 2004 | 04:00 PM | Resignation of NOMAD | |
30 Jun 2004 | 10:48 AM | Final Results | |
19 Mar 2004 | 01:30 PM | Interim Results | |
18 Sep 2003 | 07:00 AM | Temporary Suspension | |
31 Jul 2003 | 01:06 PM | Result of AGM | |
27 Jun 2003 | 07:00 AM | Final Results | |
28 Mar 2003 | 12:24 PM | Issue of Convertible Loan | |
01 Nov 2002 | 04:08 PM | Director Shareholding | |
30 Sep 2002 | 03:52 PM | Interim Results | |
26 Jul 2002 | 12:57 PM | Result of AGM | |
03 Jul 2002 | 03:37 PM | Director Shareholding | |
01 Jul 2002 | 07:00 AM | Preliminary Results | |
01 Oct 2001 | 02:35 PM | Dir Shareholding - amendment | |
01 Oct 2001 | 02:04 PM | Director Shareholding | |
28 Sep 2001 | 07:01 AM | Interim Results | |
15 Aug 2001 | 05:27 PM | Corporate Action | |
14 Aug 2001 | 06:13 PM | Corporate Action - Update | |
13 Aug 2001 | 05:57 PM | Corporate Action-Replacement | |
13 Aug 2001 | 07:51 AM | Corporate Action | |
07 Aug 2001 | 11:15 AM | Result of AGM & EGM | |
07 Aug 2001 | 09:35 AM | Fthr re Placing & Open Offer | |
17 Jul 2001 | 04:04 PM | Corporate Action | |
13 Jul 2001 | 02:59 PM | Fthr re Placing & Open Offer | |
13 Jul 2001 | 10:40 AM | Placing & Open Offer-Replace |
mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.